Expanding Clinical Pipelines, Contract Manufacturing Adoption, and Automation-Led Process Innovation Fuel Robust Market Growth Globally.Austin, United States, Feb. 27, 2026 (GLOBE NEWSWIRE) -- ...
Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...
As the CGT market evolves, developers must answer one key question that will shape their manufacturing strategy: “Should we go with a modular platform or a fully integrated system?” Both approaches ...
Cell and gene therapy (CGT) has evolved from a niche research pursuit into a central force in biopharmaceutical innovation. By engineering living cells and genetic material to repair or replace faulty ...
Manufacturing cell and gene therapies at hospitals in dedicated, GMP-accredited facilities would overcome many of the technical and logistical challenges associated with decentralized production. So ...
TOPCon Cells? BANGALORE, India, Feb. 23, 2026 /PRNewswire/ -- The global market for N-TOPCon Cells was valued at USD 10020 Million in the year 2024 and is projected to reach a revised size of USD ...
TOKYO--(BUSINESS WIRE)--PHC Corporation Biomedical Division (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura, hereinafter referred to as "Biomedical Division") will showcase a prototype ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results